Physician profile
Mackenzie Cheek
NPI 1215472360
$4,435.61
in general payments reported to CMS, 2019-2025
35 companies · $975 in 2025
The $975 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $544 · 2023: $1,116 · 2024: $1,184 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,274.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $573.65 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $511.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $446.10 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.84 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $286.00 | 2023-2025 | |
| Pfizer INC. | $224.53 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $180.55 | 2022-2025 | |
| Glaxosmithkline, LLC. | $162.18 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $151.89 | 2023-2025 | Rexulti |
| Abbvie INC. | $125.41 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.01 | 2022 | |
| Eisai INC. | $117.88 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.05 | 2023-2024 | Xifaxan |
| Amgen INC. | $111.95 | 2023-2024 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $90.51 | 2023 | Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $82.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.37 | 2022-2024 | Trintellix |
| Exact Sciences Corporation | $76.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $67.49 | 2021 | |
| Currax Pharmaceuticals LLC | $60.27 | 2021-2022 | |
| Innocoll Pharmaceuticals Limited | $50.85 | 2021 | |
| Astellas Pharma US INC | $50.29 | 2023-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $39.20 | 2021 | |
| Mylan Specialty L.P. | $38.07 | 2024 | Yupelri |
| Dexcom, INC. | $33.27 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.71 | 2022-2024 | Capvaxive, Gardasil 9, Vaxelis |
| Axsome Therapeutics, INC. | $28.67 | 2025 | Auvelity |
| C. R. Bard, INC. & Subsidiaries | $26.96 | 2023 | Purewick Female External Catheter |
| Janssen Pharmaceuticals, INC | $19.80 | 2021 | |
| Organogenesis INC. | $17.96 | 2024 | Puraply Am |
| Sanofi Pasteur INC. | $17.91 | 2025 | |
| Antares Pharma, INC. | $16.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.37 | 2024 | Voquezna |
| Arbor Pharmaceuticals, INC. | $16.23 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Cheek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.